Every 424B that NewGenIvf Group Limited (NIVF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NIVF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NIVF filings page.
NewGenIvf Group Ltd (NIVF) is offering 125,000 Class A ordinary shares at $0.07 each and 17,732,143 pre-funded warrants, and registering 17,732,143 Class A shares issuable on exercise plus up to 4,364,044 shares for resale by Vanquish Funding Group Inc., White Lion Capital LLC, and Pacific Pier Capital II, LP. Each pre-funded warrant costs $0.06999, has a $0.00001 exercise price and is immediately exercisable subject to a beneficial ownership limitation; each warrant sold reduces the ordinary shares offered one-for-one.
The best-efforts offering has no minimum and may end at NewGenIvf’s discretion before September 30, 2026. Its terms list $1,250,000 in gross proceeds, $100,000 in placement-agent fees and $1,150,000 to NewGenIvf before expenses; NewGenIvf receives no proceeds from selling-securityholder resales. NewGenIvf reported 2025 revenue of $4,726,433 versus $5,433,375 in 2024 and net income of $9,728,723 versus a $474,101 net loss. It also reports $6,262,500 in committed but unpaid consideration for an 11% PredicXion stake and identifies a risk that it may not continue as a going concern.
NewGenIvf Group Limited registers the resale of up to 100,000,000 Class A Ordinary Shares to satisfy registration rights held by certain selling securityholders, including shares issuable to White Lion Capital and JAK Opportunities VI LLC pursuant to various note conversions and warrant exercises.
The prospectus states the company is not selling any shares here and will not receive resale proceeds; however, NewGenIvf may receive up to $500,000,000 from sales to White Lion under the White Lion Purchase Agreement, subject to conditions. The prospectus lists selling methods and distributions including brokerage, block trades, and underwritten offerings.
Key context: last reported close was $0.50 (reported March 12, 2026), outstanding shares were 2,273,790 Class A and 275 Class B as of March 12, 2026, and the company regained Nasdaq minimum bid-price compliance after reverse stock splits and received transfer approval to the Nasdaq Capital Market on February 27, 2025.